What the business is, and whether it's a good one at a fair price.
Manufactures and sells pharmaceutical formulations across chronic, acute, and consumer healthcare categories in India, with an international business run through its wholly owned subsidiary Bharat Serums and Vaccines (BSV). Domestic formulations span cardiac, anti-diabetic, anti-infective and other therapy areas, while consumer healthcare covers OTC brands such as Manforce and Gasofast. The international business posted ₹605 cr in Q1 FY27 (+29% YoY) with BSV contributing to high-teens growth, and BSV holds 100% market share in anti-D in India. Consumer healthcare generated ₹246 cr in Q1 FY27, partly hit by discontinued cash-and-carry distribution. Q1 FY27 consolidated revenue was ₹4,031 cr (+13% YoY) and PAT was ₹574 cr (+29% YoY); FY26 revenue was ₹14,277.64 cr with EBITDA margin of 26.94%. Costs are dominated by employees (22.3% of revenue) and other operating expenses (24%), with materials at 16%, depreciation 6.2% and capex 4.4% of revenue.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from MANKIND PHARMA LIMITED's filed financials and exchange disclosures
MANKIND PHARMA LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol MANKIND.
Yes. Over the trailing twelve months MANKIND PHARMA LIMITED reported a net profit of ₹2,068 Cr on revenue of ₹14,738 Cr.
Yes. The dividend yield is 0.04% at the current price. It paid out 2% of its profit as dividend in FY26.
No. Debt stands at 0.38× equity, and it carries net debt of ₹5,920 Cr. That is lower than 26% of its 171 Pharmaceuticals peers.
On trailing P/E, MANKIND PHARMA LIMITED ranks 126 of 169 in Pharmaceuticals — cheaper than 26% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session MANKIND PHARMA LIMITED moves 0.91% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by MANKIND PHARMA LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
